Neptune Insurance CFO Jim Steiner to step down after annual filing

Mizuho raised its price target on Neptune Insurance (NYSE:NP) to $33 from $31, maintaining a Neutral rating. The company reported adjusted EPS of $0.17, up 44% YoY, and raised fiscal 2026 revenue guidance to $204M. Revenue grew 34% YoY, and adjusted EBITDA margin improved to 61.7%. Management also introduced fiscal 2027 guidance of $238M. InvestingPro data shows the stock trades above Fair Value.

Neptune Insurance (NP) reported record EBITDA in Q3 2026, raising 2026 guidance and providing initial 2027 outlook. CEO Trevor Burgess highlighted AI's potential to reduce costs, deep distribution relationships, and competitive advantages in the flood market. The company expects margin growth, driven by AI and new products like an upcoming earthquake offering. Strong new business premium growth was attributed to expanding into underinsured markets.

Neptune Insurance Holdings Inc. (NP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Neptune Insurance Holdings Inc. Reports Third Quarter 2026 Results ST. PETERSBURG, Fla., Oct 20, 2026 – Neptune Insurance Holdings Inc. (the “Company”) (NYSE: NP), the parent company of Neptune Flood Incorporated, has released its financial results for the third quarter of 2026 b

Teck Resources Limited reports a strike at its Highland Valley Copper mine, leading to reduced operations. Production impact remains uncertain, depending on the strike's duration, according to the company.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced lung cancer death risk by 58% in a trial. Amgen reports median survival of 21.1 months vs. 12.7 months with Imfinzi alone. Imdelltra sales grew to $288M in Q2 2026, but represents only 2.9% of Amgen's total revenue. Analysts expect Amgen's revenue to grow 4% annually through 2030.

Johnson & Johnson reported positive results for its investigational drug JNJ-6143 in a Phase 1 prostate cancer trial, with 77% of patients showing a confirmed PSA decline. The company selected a 50-mg daily dose for Phase 2 testing. The drug is designed to target the androgen receptor and BRD4 protein. Johnson & Johnson acquired Halda Therapeutics, the drug's original developer, for $3.05 billion in 2025.